Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients
Br J Dermatol
.
2021 Mar;184(3):561-563.
doi: 10.1111/bjd.19577.
Epub 2020 Nov 18.
Authors
E Nettis
1
,
G Fabbrocini
2
,
M Ortoncelli
3
,
G Pellacani
4
,
G Argenziano
5
,
E Di Leo
6
,
C Patruno
7
,
L Stingeni
8
,
C Foti
9
,
F Rongioletti
10
,
L Macchia
1
,
S Tavecchio
11
12
,
M Napolitano
13
,
S Ribero
3
,
L Bonzano
14
,
G Calabrese
5
,
D Di Bona
1
,
S P Nisticò
7
,
K Hansel
8
,
P Romita
9
,
V Piras
10
,
M Carbonara
15
,
A Detoraki
16
,
S M Ferrucci
11
Affiliations
1
University of Bari - Aldo Moro.
2
University of Naples Federico II.
3
University of Turin.
4
University of Modena and Reggio Emilia.
5
University of Campania.
6
Unit of Internal Medicine-"F. Miulli" Hospital, Acquaviva delle Fonti.
7
University Magna Graecia of Catanzaro.
8
University of Perugia.
9
Unit of Dermatology, University of Bari.
10
University of Cagliari.
11
UOC Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.
12
Università degli Studi di Milano.
13
University of Molise.
14
AUSL Modena.
15
National Institute of Statistics (ISTAT).
16
Azienda Ospedaliera Universitaria Federico II.
PMID:
32998177
DOI:
10.1111/bjd.19577
No abstract available
Publication types
Letter
MeSH terms
Adult
Antibodies, Monoclonal, Humanized
Dermatitis, Atopic* / drug therapy
Eczema*
Humans
Substances
Antibodies, Monoclonal, Humanized
dupilumab